Fierce Biotech

Updated: Feb 7, 2020

Insilico and A2A launched new Deuchenne-focused AI drug company

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology...